Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disease of the central nervous system, primarily affecting the optic nerves and spinal cord. Once thought to be a variant of Multiple Sclerosis (MS), it is now recognized as a distinct condition. NMOSD is characterized by acute inflammatory attacks that cause vision loss and spinal cord dysfunction. Unlike ALS or degenerative diseases such as SCA, its core mechanism is immune-mediated damage to nervous tissue.

Overview

NMOSD arises when the immune system attacks specific CNS cells, mainly astrocytes, often associated with antibodies against aquaporin-4 (AQP4-IgG). These attacks trigger optic neuritis and transverse myelitis, leading to severe symptoms with incomplete recovery. NMOSD is more common in women (female-to-male ratio 3–9:1), with typical onset between ages 30–40, though it can occur in children or older adults.

Classification

• AQP4-IgG positive NMOSD
  • Most common (70–90% of patients).
  • Strongly linked to optic nerve and spinal cord lesions.
• AQP4-IgG negative NMOSD
  • Less common; may involve other antibodies (e.g., MOG-IgG) or unidentified ones.
  • Symptoms are similar, but course and prognosis may differ.

Brain involvement (brainstem or cerebral lesions) also falls within the NMOSD spectrum.

Symptoms

NMOSD presents with acute attacks:

• Optic neuritis: sudden vision loss (one or both eyes, possibly blindness), eye pain (especially with movement), visual field defects
• Transverse myelitis: limb weakness or paralysis, sensory loss (numbness, tingling), bladder/bowel dysfunction
• Other possible symptoms: persistent vomiting or hiccups (brainstem involvement), confusion or seizures (cerebral involvement)

Between attacks, patients may be symptom-free, but disability accumulates with each relapse.

Causes

• Autoimmunity:
  • AQP4 antibodies attack aquaporin-4 channels on astrocytes, causing inflammation and demyelination.
  • Some cases involve MOG antibodies (myelin oligodendrocyte glycoprotein).
• Triggers:
  • Viral infections or vaccines may initiate immune responses.
  • Other autoimmune diseases (e.g., lupus, Sjögren’s syndrome) increase risk.
• Genetic predisposition:
  • Not directly inherited, but certain HLA variants may increase susceptibility.

Diagnosis

Diagnosis distinguishes NMOSD from MS, based on 2015 international consensus:

• Core criteria:
  • AQP4-IgG positive: ≥1 attack of optic neuritis or myelitis.
  • AQP4-IgG negative: ≥2 attacks in different regions, excluding other causes.
• Supporting evidence:
  • Serology: AQP4-IgG detection (highly specific)
  • MRI: optic nerve enhancement; spinal cord lesions spanning ≥3 vertebral segments; brainstem/dorsal brain lesions
  • CSF: elevated white cells, but no MS-type oligoclonal bands

Treatment

Management includes acute attack control and long-term prevention:

1. Acute attacks
   • High-dose steroids (e.g., IV methylprednisolone 1g/day for 3–5 days)
   • Plasma exchange (PLEX) if steroids fail
2. Long-term prevention (immunosuppression)
   • Rituximab: targets B cells, reduces antibody production
   • Azathioprine or Mycophenolate Mofetil: broad immunosuppressants
   • Eculizumab / Ravulizumab: complement inhibitors, FDA-approved in 2019, markedly reduce relapses
   • Satralizumab or Inebilizumab: newer targeted therapies
3. Symptom management
   • Neuropathic pain: Gabapentin
   • Physical therapy for functional recovery

Prognosis

• Without treatment: each attack leaves permanent disability (blindness, paralysis), poor outcomes
• With treatment: early immunosuppression reduces relapses, improves quality of life
• Life expectancy: relatively preserved if well-controlled; otherwise, late-stage death from respiratory failure or infections

Differences from Other Diseases

• NMOSD vs. MS: NMOSD attacks are more severe, recovery poorer; lesions mainly optic nerve and long spinal cord segments; AQP4 antibodies present in NMOSD but not MS.
• NMOSD vs. ALS: NMOSD is immune-inflammatory; ALS is motor neuron degeneration. NMOSD lacks fasciculations; ALS lacks optic neuritis.
• NMOSD vs. SCA: NMOSD is acute and relapsing; SCA is chronic progressive cerebellar degeneration.

Latest Developments

• New drugs: Satralizumab (IL-6 inhibitor) expands treatment options
• MOGAD distinction: MOG antibody-associated disease now recognized separately, with better prognosis
• Improved diagnostics: more sensitive antibody testing enables earlier detection

Update: 1/5/2026